New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
06:00 EDTAZNAstraZeneca announces sale of Alderley Park, to take impairment charges
AstraZeneca announced the sale of its Alderley Park site in Cheshire, U.K., to Manchester Science Parks, a Greater Manchester based public-private partnership and science park operator. The sale is part of AstraZeneca’s plan, set out in March 2013, to establish a new global R&D centre and corporate headquarters in Cambridge, U.K., in 2016. AstraZeneca will take pre-tax impairment charges of $275M to non-core R&D expense in 1Q14. This forms part of the costs associated with the footprint changes announced in March 2013.AstraZeneca expects to complete the sale by end of March 2014 and will remain a key tenant on the site. The handover of the site will be phased over a three year period, with the full exit of AstraZeneca R&D staff to take place in line with the completion of the company’s new facility in Cambridge.
News For AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
07:31 EDTAZNLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
08:02 EDTAZNAstraZeneca says SYMBICORT results published in journal
Subscribe for More Information
September 29, 2015
08:07 EDTAZNAstraZeneca says Brilinta 60-mg tablets now available in U.S. pharmacies
Subscribe for More Information
September 28, 2015
07:52 EDTAZNIIR Holdings to hold a conference
Subscribe for More Information
September 25, 2015
07:22 EDTAZNEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 22, 2015
08:02 EDTAZNAstraZeneca to present 33 abstracts from respiratory disease portfolio at ERS
Subscribe for More Information
07:43 EDTAZNDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
07:17 EDTAZNAstraZeneca eyes crowd sourcing for better cancer drug cocktails, Reuters says
AstraZeneca's decision release preclinical data from over 50 of its medicines is "unprecedented" in scale and will speed up the hunt for tumor-fighting drug combinations, Reuters says. The company is aiming for a crowd sourcing initiative to help mix the future's cancer drug cocktails, the report says. Reference Link
06:19 EDTAZNClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
14:28 EDTAZNTuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
11:24 EDTAZNHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use